Cargando…
Cefepime/convalescent-anti-sars-cov-2-plasma/rituximab: Relapsed COVID-19 and lack of efficacy following off-label use: 2 case reports
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226601/ http://dx.doi.org/10.1007/s40278-022-17842-y |
Ejemplares similares
-
Convalescent-anti-sars-cov-2-plasma/dexamethasone/rituximab: Depletion of B-lymphocytes, lack of efficacy and off label treatment: case report
Publicado: (2022) -
Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2021) -
Convalescent-anti-SARS-CoV-2-plasma: Lack of efficacy following off-label use: case report
Publicado: (2022) -
Convalescent-anti-sars-cov-2-plasma/dexamethasone/remdesivir: Lack of efficacy and off label use: case report
Publicado: (2022) -
Convalescent-anti-SARS-CoV-2-plasma/remdesivir/rituximab: COVID-19 infection, and lack of efficacy following off-label use: 20 case reports
Publicado: (2022)